宫腔镜切除子宫内膜息肉中与恶性相关的因素:系统综述与荟萃分析
本系统综述与荟萃分析纳入37项研究共21,057例子宫内膜息肉患者,评估癌前及恶性病变的检出频率及相关临床与人口学因素。癌前及恶性病变的总患病率为3.4%(95%CI 2.8-4.1)。异常子宫出血、绝经状态、年龄>60岁、糖尿病、系统性动脉高血压、肥胖及他莫昔芬使用与息肉恶性相关,而乳腺癌、激素治疗、产次及息肉大小与恶性无显著关联。
要点
- 子宫内膜息肉中癌前及恶性病变的患病率为3.4%(95%CI 2.8-4.1)。
- 年龄>60岁、绝经、异常子宫出血、糖尿病、高血压、肥胖及他莫昔芬使用与息肉恶性相关。
- 乳腺癌、激素治疗、产次及息肉大小与息肉恶性无显著关联。
核心结论
- 每100例临床诊断的子宫内膜息肉患者中约有3例存在癌前或恶性病变。
- 息肉恶性与特定的临床及人口学因素相关。
研究设计与样本
- 系统综述与荟萃分析,检索主要数据库及灰色文献。
- 纳入37项研究,共21,057例子宫内膜息肉患者。
- 由独立研究者筛选文献并提取数据,采用随机效应模型及荟萃回归分析。
主要发现
- 癌前及恶性病变的患病率为3.4%(95%CI 2.8-4.1;I²=80.5%)。
- 异常子宫出血的患病率比(PR)为1.47(95%CI 1.27-1.69;I²=82.4%)。
- 绝经状态的PR为1.67(95%CI 1.48-1.89;I²=78.4%),年龄>60岁的PR为2.41(95%CI 1.84-3.16;I²=81.5%)。
- 糖尿病的PR为1.76(95%CI 1.43-2.16;I²=0.0%),系统性动脉高血压的PR为1.50(95%CI 1.20-1.88;I²=75.9%),肥胖的PR为1.41(95%CI 1.13-1.76;I²=41.2%),他莫昔芬使用的PR为1.53(95%CI 1.06-2.21;I²=0.0%)。
- 乳腺癌的PR为0.83(95%CI 0.44-1.57;I²=0.0%),激素治疗的PR为0.93(95%CI 0.67-1.30;I²=31.7%),产次的PR为0.87(95%CI 0.39-1.96;I²=78.1%),息肉大小的PR为1.05(95%CI 0.70-1.57;I²=44.7%),均与息肉恶性无显著关联。
关键数值与推荐
- 癌前及恶性病变患病率为3.4%(95%CI 2.8-4.1;I²=80.5%)。
- 年龄>60岁的PR为2.41(95%CI 1.84-3.16;I²=81.5%),绝经状态的PR为1.67(95%CI 1.48-1.89;I²=78.4%)。
- 异常子宫出血的PR为1.47(95%CI 1.27-1.69;I²=82.4%),糖尿病的PR为1.76(95%CI 1.43-2.16;I²=0.0%)。
- 系统性动脉高血压的PR为1.50(95%CI 1.20-1.88;I²=75.9%),肥胖的PR为1.41(95%CI 1.13-1.76;I²=41.2%),他莫昔芬使用的PR为1.53(95%CI 1.06-2.21;I²=0.0%)。
- 乳腺癌、激素治疗、产次及息肉大小与恶性无显著关联(PR分别为0.83、0.93、0.87、1.05,95%CI均包含1)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
In this study, we aimed to estimate the frequency of premalignant and malignant lesions in endometrial polyps, and to evaluate associated clinical and demographic factors. A literature search was performed in major databases and the gray literature using the terms polyps OR endometrial polyp AND endometrial neoplasms OR endometrial cancer OR endometrial hyperplasia OR malignan*. Studies describing the frequency of premalignant and malignant lesions in endometrial polyps and any clinical or demographic factors associated with malignant lesions extracted using hysteroscopy were considered eligible. Independent investigators selected the studies and extracted the data. A meta-analysis was performed using a random-effects model and meta-regression. We identified 37 studies (comprising 21,057 patients) of endometrial polyps. The prevalence of premalignant and malignant lesions was 3.4% (95% confidence interval [CI], 2.8-4.1; I2, 80.5%). Abnormal uterine bleeding (prevalence ratio [PR], 1.47; 95% CI, 1.27-1.69; I2, 82.4%), menopausal status (PR, 1.67; 95% CI, 1.48-1.89; I2, 78.4%), age >60 years (PR, 2.41; 95% CI, 1.84-3.16; I2, 81.5%), diabetes mellitus (PR, 1.76; 95% CI, 1.43-2.16; I2, 0.0%), systemic arterial hypertension (PR, 1.50; 95% CI, 1.20-1.88; I2, 75.9%), obesity (PR, 1.41; 95% CI:1.13-1.76; I2, 41.2%), and tamoxifen use (PR, 1.53; 95% CI, 1.06-2.21; I2, 0.0%) were associated with endometrial polyp malignancy. However, breast cancer (PR, 0.83; 95% CI, 0.44-1.57; I2, 0.0%), hormonal therapy (PR, 0.93; 95% CI, 0.67-1.30; I2, 31.7%), parity (PR, 0.87; 95% CI, 0.39-1.96; I2, 78.1%), and endometrial polyp size (PR, 1.05; 95% CI, 0.70-1.57; I2, 44.7%) were not associated with malignancy of endometrial polyps. Three of every 100 women with clinically recognized polyps, a condition associated with specific clinical and demographic factors, will harbor premalignant or malignant lesions.
引用
- Sasaki LMP, Andrade KRC, Figueiredo ACMG, et al. Factors Associated with Malignancy in Hysteroscopically Resected Endometrial Polyps: A Systematic Review and Meta-Analysis. J Minim Invasive Gynecol. 2018. PMID: 29454147. doi:10.1016/j.jmig.2018.02.004
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。